EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Metabolomic profiling of aluminum chloride-intoxicated rats treated with novel dual inhibitors targeting acetylcholinesterase for Alzheimer’s therapy

Samir H. I. Haggag, Noha S. Hussein, Abdel-Hamid Z. Abdel-Hamid, Hanan F. Aly, Eman A. Younis, Asmaa F. Aboul-Naser, Maha Z. Rizk

Advanced Neurology · 2026-05-12 · 5 (4) · 025510129

DOI: 10.36922/an025510129 ↗
AbstractBibliografische Angaben

Abstract

Millions of elderly people worldwide have Alzheimer’s disease (AD), a complex and progressive neurological illness. AD can only be definitively diagnosed postmortem by examining brain tissue obtained during autopsy, which makes detection and intervention challenging. Therefore, identifying specific metabolites as potential metabolic biomarkers associated with AD risk is crucial. For a comprehensive understanding of the role of metabolic biomarkers in AD etiology, we performed metabolomics-based gas chromatography–mass spectrometry to characterize serum metabolite alterations in rats with AlCl3-induced AD-like neurotoxicity. We evaluated metabolite levels across five experimental groups (10 rats per group). We further conducted metabolic profiling to identify metabolomic features associated with AD risk and to assess the therapeutic effects of newly synthesized compounds, including benzofuran-derivative-7 (MP19) and coumarin-3 (MP27). Four metabolites identified in this study provided strong discriminative power for AD diagnosis, offering a potential approach for biomarker detection that may enhance patient diagnosis and prognosis in the future. This study provides new insights into the etiology, early detection, and potential therapy for AD, involving blood-based metabolic biomarkers that warrant further investigation.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →